Avacta Group Plc
AVCT.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$399.78M
Close$
$0.19
99.7% downside
Current Fair Value
99.7% downsideOvervalued by 99.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $399.78 Million |
|---|---|
| Enterprise Value | $399.38 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.1 |
| Beta | -0.11 |
| Outstanding Shares | 449,438,000 |
Return
| Return on Equity | -1888.74% |
|---|---|
| Return on Assets | -230.07% |
| Return on Invested Capital | -1593.80% |
Valuation & Multiples
| P/E Ratio | -7.18 |
|---|---|
| PEG | -91.15 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 34.94 |
| Enterprise Value to EBIT | -6.63 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 5.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$56,000
Average shareholder expectationNext Earnings Call
Expected Date
April 22, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$51,133
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Avacta Group Plc
154 employees
CEO: Christina Marie Coughlin Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, levera...